(1r,3s,5R,7S)-N-phenethyl-2-oxaadamantan-1-amine | 1160355-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (1r,3s,5R,7S)-N-phenethyl-2-oxaadamantan-1-amine
• 英文别名: N-(2-phenylethyl)(2-oxaadamant-1-yl)amine；N-(2-phenylethyl)-2-oxatricyclo[3.3.1.13,7]decan-1-amine
• CAS: 1160355-48-5
• 化学式: C₁₇H₂₃NO
• 分子量: 257.376
• InChiKey: LQFQRQZRFYWYCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1r,3s,5R,7S)-N-phenethyl-2-oxaadamantan-1-amine 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 以2.94 g的产率得到N-(2-phenylethyl)(2-oxaadamant-1-yl)amine hydrochloride
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines

  摘要：

  The synthesis of several (2-oxaadamant-1-yl) amines is reported. They were evaluated as NMDA receptor antagonists and several of them were more active than amantadine, but none was more potent than memantine. None of the tested compounds displayed antiviral activity. Two of the derivatives showed a significant level of trypanocidal activity. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.02.007
• 作为产物：
  描述：

  二环[3.3.1]壬-3,7-二酮 、 2-苯乙胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 6.0h， 生成 (1r,3s,5R,7S)-N-phenethyl-2-oxaadamantan-1-amine
  参考文献：
  名称：

  COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION

  摘要：

  这项发明涉及含有金刚烷基团或其类似物的新化合物的抗肿瘤活性。该发明还涉及利用这种含有金刚烷基团的S、P、T结构的化合物与立体异构体、互变异构体、前药、药用盐、复杂盐或溶剂化物的结合来治疗抗肿瘤和其他疾病的药物应用，这些抗肿瘤剂具有以下一般公式：

  公开号：

  US20140045779A1

文献信息

• COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION
  申请人：Xu Lifeng

  公开号：US20140045779A1

  公开（公告）日：2014-02-13

  This invention relates with anti-tumor activities of new compounds containing an adamantyl group or analogs thereof. The invention also relates with the medication applications of anti-tumor and other diseases by this kind of compounds with the combination of S, P, T structures containing adamantyl group and the formation of stereoisomer, tautomers, prodrug, pharmaceutically acceptable salts, complex salts or solvates to their anticancer application and anticancer agents, which have the following general formula:

  这项发明涉及含有金刚烷基团或其类似物的新化合物的抗肿瘤活性。该发明还涉及利用这种含有金刚烷基团的S、P、T结构的化合物与立体异构体、互变异构体、前药、药用盐、复杂盐或溶剂化物的结合来治疗抗肿瘤和其他疾病的药物应用，这些抗肿瘤剂具有以下一般公式：
• Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines
  作者：María D. Duque、Pelayo Camps、Lenuta Profire、Silvia Montaner、Santiago Vázquez、Francesc X. Sureda、Jordi Mallol、Marta López-Querol、Lieve Naesens、Erik De Clercq、S. Radhika Prathalingam、John M. Kelly

  DOI：10.1016/j.bmc.2009.02.007

  日期：2009.4

  The synthesis of several (2-oxaadamant-1-yl) amines is reported. They were evaluated as NMDA receptor antagonists and several of them were more active than amantadine, but none was more potent than memantine. None of the tested compounds displayed antiviral activity. Two of the derivatives showed a significant level of trypanocidal activity. (C) 2009 Elsevier Ltd. All rights reserved.